{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=10",
    "query": {
      "intervention": "0.9 % sodium chloride",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 2427,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:50:21.177Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04863248",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Small Cell Lung Cancer",
        "NSCLC",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-04-30",
      "completion_date": "2022-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04863248"
    },
    {
      "nct_id": "NCT04640038",
      "title": "Contrast Enhanced Ultrasound in COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19",
        "Multisystem Inflammatory Syndrome in Children (MIS-C)"
      ],
      "interventions": [
        {
          "name": "Sulfur hexafluoride lipid-type A microspheres",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Minute to 17 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-12-18",
      "completion_date": "2021-09-17",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640038"
    },
    {
      "nct_id": "NCT02219321",
      "title": "Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Lidocaine infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2014-12",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2020-03-25",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219321"
    },
    {
      "nct_id": "NCT05730816",
      "title": "MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Magnesium sulfate",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2023-04-04",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05730816"
    },
    {
      "nct_id": "NCT00137293",
      "title": "Study Evaluating GAP-486 in Heart Rhythm",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arrhythmia"
      ],
      "interventions": [
        {
          "name": "GAP-486 (ZP-123)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride, USP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2005-11",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2007-12-10",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Hershey, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00137293"
    },
    {
      "nct_id": "NCT01844206",
      "title": "Two Dose Epidural Morphine for Post-cesarean Analgesia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Morphine Adverse Reaction"
      ],
      "interventions": [
        {
          "name": "Epidural Morphine",
          "type": "DRUG"
        },
        {
          "name": "Epidural Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2013-06",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-12-23",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844206"
    },
    {
      "nct_id": "NCT03360214",
      "title": "PEMF and PEC Blocks in Mastectomy Reconstruction Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer Female"
      ],
      "interventions": [
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drug",
          "type": "OTHER"
        },
        {
          "name": "Pulsed Electromagnetic Field (PEMF) Device",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Device",
          "type": "OTHER"
        },
        {
          "name": "Ropivacaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2017-07-05",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03360214"
    },
    {
      "nct_id": "NCT00238433",
      "title": "Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 37,
      "start_date": "2005-03",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-27",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00238433"
    },
    {
      "nct_id": "NCT01014650",
      "title": "Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "GLYX-13",
          "type": "DRUG"
        },
        {
          "name": "IV normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Naurex, Inc, an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2009-11",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-02-22",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01014650"
    },
    {
      "nct_id": "NCT02081326",
      "title": "Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type One",
        "Diabetes Mellitus, Type I",
        "Autoimmune Diabetes",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Bacillus Calmette-Guérin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2015-06",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-14T14:50:21.177Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02081326"
    }
  ]
}